BioCentury | Jun 26, 2020
Emerging Company Profile

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

...VC syndicate that includes co-lead investors 5AM Ventures, venBio and RA Capital as well as Medivate Partners...
...Corp. Number of employees: 10 Funds raised: $78 million Investors: 5AM Ventures, venBio, RA Capital, Medivate Partners...
BioCentury | Jun 22, 2018
Financial News

Qiming leads series B for cancer play WindMIL

...18 in an untranched series B round led by Qiming Venture Partners. Fellow new investors Medivate Partners...
BioCentury | Jun 18, 2018
Financial News

Qiming leads series B for cancer play WindMIL

...million in an untranched series B round led by Qiming Venture Partners. Fellow new investors Medivate Partners...
BioCentury | Dec 10, 2016
Finance

SillaJen slides onto KOSDAQ

...In March, SillaJen Inc. raised $37 million in a venture round, including $12 million from Medivate Partners...
BioCentury | Mar 28, 2016
Financial News

SillaJen completes venture financing

...Busan, South Korea Business: Cancer Date completed: 2016-03-21 Type: Venture financing Raised: $37 million Investors: Medivate Partners...
BioCentury | Mar 25, 2016
Financial News

SillaJen raises $37M in venture round

...Inc. (Busan, South Korea) raised $37 million in a venture round, including $12 million from Medivate Partners...
BioCentury | Apr 29, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) gained $0.09 to $3.29 on Friday after EMA's CHMP backed an MAA for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). The company markets the product in the U.S. for...
BioCentury | Jan 7, 2013
Company News

Aragon Pharmaceuticals, Medivation, University of California news

The court has not yet ruled on Medivation's claim that the university improperly disclosed information to Aragon about the compounds covered in the 2005 deal and directed the parties to decide on a date to...
BioCentury | Dec 27, 2012
Company News

Court rules Medivation has no rights to ARN-509

A California state court ruled that Medivation Inc. (NASDAQ:MDVN) does not have rights to ARN-509 , a second-generation androgen receptor antagonist from Aragon Pharmaceuticals Inc. (San Diego, Calif.). In February 2011, Medivation filed suit against the...
BioCentury | Nov 2, 2012
Financial News

Astellas reports first Xtandi sales

Medivation Inc. (NASDAQ:MDVN) recorded $14 million in U.S. sales of prostate cancer drug Xtandi enzalutamide since the drug's launch in September, according to fiscal 1H13 earnings reported by Astellas Pharma Inc. (Tokyo:4503) on Thursday. FDA...
Items per page:
1 - 10 of 17
BioCentury | Jun 26, 2020
Emerging Company Profile

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

...VC syndicate that includes co-lead investors 5AM Ventures, venBio and RA Capital as well as Medivate Partners...
...Corp. Number of employees: 10 Funds raised: $78 million Investors: 5AM Ventures, venBio, RA Capital, Medivate Partners...
BioCentury | Jun 22, 2018
Financial News

Qiming leads series B for cancer play WindMIL

...18 in an untranched series B round led by Qiming Venture Partners. Fellow new investors Medivate Partners...
BioCentury | Jun 18, 2018
Financial News

Qiming leads series B for cancer play WindMIL

...million in an untranched series B round led by Qiming Venture Partners. Fellow new investors Medivate Partners...
BioCentury | Dec 10, 2016
Finance

SillaJen slides onto KOSDAQ

...In March, SillaJen Inc. raised $37 million in a venture round, including $12 million from Medivate Partners...
BioCentury | Mar 28, 2016
Financial News

SillaJen completes venture financing

...Busan, South Korea Business: Cancer Date completed: 2016-03-21 Type: Venture financing Raised: $37 million Investors: Medivate Partners...
BioCentury | Mar 25, 2016
Financial News

SillaJen raises $37M in venture round

...Inc. (Busan, South Korea) raised $37 million in a venture round, including $12 million from Medivate Partners...
BioCentury | Apr 29, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) gained $0.09 to $3.29 on Friday after EMA's CHMP backed an MAA for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). The company markets the product in the U.S. for...
BioCentury | Jan 7, 2013
Company News

Aragon Pharmaceuticals, Medivation, University of California news

The court has not yet ruled on Medivation's claim that the university improperly disclosed information to Aragon about the compounds covered in the 2005 deal and directed the parties to decide on a date to...
BioCentury | Dec 27, 2012
Company News

Court rules Medivation has no rights to ARN-509

A California state court ruled that Medivation Inc. (NASDAQ:MDVN) does not have rights to ARN-509 , a second-generation androgen receptor antagonist from Aragon Pharmaceuticals Inc. (San Diego, Calif.). In February 2011, Medivation filed suit against the...
BioCentury | Nov 2, 2012
Financial News

Astellas reports first Xtandi sales

Medivation Inc. (NASDAQ:MDVN) recorded $14 million in U.S. sales of prostate cancer drug Xtandi enzalutamide since the drug's launch in September, according to fiscal 1H13 earnings reported by Astellas Pharma Inc. (Tokyo:4503) on Thursday. FDA...
Items per page:
1 - 10 of 17